Can I read Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment on EtoBox?

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment by Koichi Node; Teruo Inoue; Valentin Boyko; Ilan Goldberg; Enrique Z Fisman; Yehuda Adler; Ehud Schwammenthal; Zipora Matas; Solomon Behar; Alexander Tenenbaum is a Medicine article available to read on EtoBox.

What is Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment about?

## Abstract ## Background The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment. ## Methods Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study. They presented with New York Heart Association (NYHA) functional class III, comprising 58 patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective, double-blind, placebo-controlled follow-up. ## Results During follow-up ProBNP level did not change significantly in the placebo group, whereas it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP values. No significant differences between the groups were found for ProBNP levels after 2 year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline P

Who reads Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment?

Author

Koichi Node; Teruo Inoue; Valentin Boyko; Ilan Goldberg; Enrique Z Fisman; Yehuda Adler; Ehud Schwammenthal; Zipora Matas; Solomon Behar; Alexander Tenenbaum

Publisher

BioMed Central; Springer (Biomed Central Ltd.); London: BioMed Central, 2002-; Springer Science and Business Media LLC; Society for Mining, Metallurgy and Exploration Inc. (ISSN 1475-2840)

Published

2009

Language

EN

Field

Medicine (Health Sciences)